Recapturing Immune Tolerance to Pegloticase for the Management of Tophaceous Gout
Status:
Enrolling by invitation
Trial end date:
2027-02-01
Target enrollment:
Participant gender:
Summary
This safety and feasibility, open-label study of up to 9 subjects will examine a group of
subjects with poorly controlled tophaceous gout (intolerant to or ineffective oral urate
lowering agents and loss of prior Pegloticase response) pre-treated with Rituximab to
recapture response to Methotrexate-Pegloticase.